AI-driven drug developer AQEMIA has announced a notable breakthrough in its joint research partnership with pharmaceutical company Servier. The company's study has identified molecules effective toward an undruggable target in immuno-oncology. This achievement will grant AQEMIA a milestone payment of an undisclosed amount.

The partnership was initiated in December 2021 to accelerate drug discovery in immuno-oncology using AQEMIA’s cutting-edge AI technology and deep physics. The company conducts research for several internal therapeutic programs in relevant fields such as oncology, immunology, inflammation, and neurological disorders.